StreetInsider.com News Articles

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Thu, 08 Oct 2026 16:30:00 -0400

Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial

New preclinical data evaluating NBD1 stabilizers in combination with other CFTR modulators across F508del genotype groups demonstrated the potential of NBD1 stabilizer-based combinations to benefit a broad population of people with CF

WALTHAM, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced data being presented at the 2026 North American Cystic

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Thu, 08 Oct 2026 16:30:00 -0400

Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial

Form 8-K Sionna Therapeutics, For: Sep 09

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091834.html

Form 4 Sionna Therapeutics, For: Sep 17 Filed by: RA Capital Nexus Fund, L.P.

Mon, 21 Sep 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260921/27086327.html

Form SCHEDULE 13D/A Sionna Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 21 Sep 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260921/27086329.html

Form 4 Sionna Therapeutics, For: Sep 17 Filed by: Ridloff Elena

Fri, 18 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260918/27081169.html

Form 4 Sionna Therapeutics, For: Sep 17 Filed by: McKee Charlotte

Fri, 18 Sep 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260918/27081166.html

Form 4 Sionna Therapeutics, For: Sep 17 Filed by: Fitzpatrick Jennifer

Fri, 18 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260918/27081157.html

Form 4 Sionna Therapeutics, For: Sep 17 Filed by: Cloonan Michael

Fri, 18 Sep 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260918/27081125.html

Form 144 Sionna Therapeutics, Filed by: RA Capital Healthcare Fund LP

Thu, 17 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260917/27076751.html

Sionna Therapeutics (SION) Reiterated at Hold by Stifel - 'Remains a Show Me Story'

Tue, 15 Sep 2026 09:19:32 -0400

(Updated - September 15, 2026 9:19 AM EDT)

Stifel analyst Paul Matteis reiterated a Hold rating and $7.00 price target on Sionna Therapeutics (NASDAQ: SION).

The analyst commented, "SION this evening showed various post-hoc analyses of their negative ph2a study, and after this they remain hopeful on the NBD1 mechanism, announcing plans to advance their NBD1 dual-combo of SION-451/ SION-2222 into a ph2a. Explaining the recent negative result for the SION-719 addon study, post-hoc analyses identified various factors: (1) PK outliers with three of the 14 participants having lower drug exposures suggestive of noncompliance, (2) reduced Trikafta exposures during the SION-719 treatment

Sionna Therapeutics (SION) Reiterated at Market Perform by Citizens Amid Ph2a Trial Issues

Tue, 15 Sep 2026 04:42:03 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Perform rating on Sionna Therapeutics (NASDAQ: SION).

The analyst commented, "New analysis of the Phase 2a PreciSION CF trial points to trial-specific issues, which leave optimism for NBD1 stabilization that management hopes is further supported by an upcoming Phase 2a trial of the SION-451/SION-2222 combo; we reiterate our Market Perform rating. SION shares ended at ~1.6x our YE26 cash estimate of ~$236M, and we anticipate the stock to continue to trade near these levels as skepticism on the NBD1 thesis will likely remain until Phase 2a data that may not come until later in

Form 8-K Sionna Therapeutics, For: Sep 09

Mon, 14 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260914/27058494.html

Sionna cuts 46% of staff, pivots to new CF drug combination

Mon, 14 Sep 2026 16:01:19 -0400

Sionna Therapeutics (Nasdaq: SION) announced plans to advance its SION-451 + SION-2222 dual combination into a Phase 2a proof-of-concept trial for cystic fibrosis, while also disclosing a 46% workforce reduction and other cost-saving measures.

The Waltham, Mass.-based company said the AscenSION CF trial is expected to initiate in the first quarter of 2027. The open-label trial will evaluate adults with CF who are homozygous for F508del, treating participants with SION-451 + SION-2222 for 28 days after switching from Trikafta. The trial will assess sweat chloride, safety, and pharmacokinetics.

The decision follows a post hoc analysis of the company's earlier PreciSION CF Phase

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

Mon, 14 Sep 2026 16:01:00 -0400

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity

Dual combination Phase 2a trial expected to initiate in first quarter of 2027

46% workforce reduction and other cost-saving measures prioritize advancing the dual combination program and extend cash runway into the second half of 2029

Sionna to host conference call today at 4:30 p.m. ET

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

Mon, 14 Sep 2026 16:01:00 -0400

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity

Dual combination Phase 2a trial expected to initiate in first quarter of 2027

46% workforce reduction and other cost-saving measures prioritize advancing the dual combination program and extend cash runway into the second half of 2029

Sionna to host conference call today at 4:30 p.m. ET

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a

Freedom Broker Downgrades Sionna Therapeutics (SION) to Hold

Tue, 11 Aug 2026 10:09:06 -0400

Freedom Broker analyst Ilya Zubkov downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold with a price target of $5.00.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $4.50 yesterday.

Jones Trading Downgrades Sionna Therapeutics (SION) to Hold

Mon, 10 Aug 2026 15:53:12 -0400

Jones Trading analyst Debanjana Chatterjee downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

LifeSci Capital Downgrades Sionna Therapeutics (SION) to Market Perform

Mon, 10 Aug 2026 15:21:56 -0400

LifeSci Capital analyst Gaurav Maini downgraded Sionna Therapeutics (NASDAQ: SION) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

BTIG Downgrades Sionna Therapeutics (SION) to Neutral, 'we were wrong on our PreciSION CF call'

Mon, 10 Aug 2026 15:14:56 -0400

BTIG analyst Kambiz Yazdi downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

The analyst comments "We will be straightforward: we were wrong on our PreciSION CF call. PreciSION CF did not meet its key activity endpoint, reporting a mean placebo-adjusted sweat chloride change of -1.0 mmol/L (p=0.7), well short of the ≥10 mmol/L threshold we anticipated and that the trial was powered to detect. We are downgrading SION to Neutral."

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

BTIG Downgrades Sionna Therapeutics (SION) to Neutral, 'we were wrong on our PreciSION CF call'

Mon, 10 Aug 2026 15:14:56 -0400

BTIG analyst Kambiz Yazdi downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

Guggenheim Downgrades Sionna Therapeutics (SION) to Neutral

Mon, 10 Aug 2026 13:16:27 -0400

(Updated - August 10, 2026 1:16 PM EDT)

Guggenheim analyst Yatin Suneja downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

The analyst commented: "Sionna's preciSION study of its NBD1 stabilizer combined with Vertex's Trikafta failed to show clinical benefit, and the program will be discontinued as management reassesses combo strategy. SION-451 (BID) + SION-2222 (TMD1 corrector, QD) is now the preferred pairing based on target coverage. Further profile updates are expected once management digests preciSION results. While NBD1 remains a differentiated biological target, we are moving to the sidelines pending more clarity. Current cash/basic share is ~$5.95. Downgrade to NEUTRAL and

Guggenheim Downgrades Sionna Therapeutics (SION) to Neutral

Mon, 10 Aug 2026 13:16:27 -0400

(Updated - August 10, 2026 1:16 PM EDT)

Guggenheim analyst Yatin Suneja downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

RBC Capital Upgrades Sionna Therapeutics (SION) to Sector Perform

Mon, 10 Aug 2026 11:46:29 -0400

RBC Capital analyst Brian Abrahams upgraded Sionna Therapeutics (NASDAQ: SION) from Underperform to Sector Perform with a price target of $5.00.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

Citizens Downgrades Sionna Therapeutics (SION) to Market Perform

Mon, 10 Aug 2026 11:45:48 -0400

Citizens analyst Jonathan Wolleben downgraded Sionna Therapeutics (NASDAQ: SION) from Market Outperform to Market Perform.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.